These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9557697)

  • 1. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.
    Bembridge GP; Lopez JA; Cook R; Melero JA; Taylor G
    J Virol; 1998 May; 72(5):4080-7. PubMed ID: 9557697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.
    Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G
    J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo.
    Aung S; Tang YW; Graham BS
    J Virol; 1999 Nov; 73(11):8944-9. PubMed ID: 10515999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection.
    Srikiatkhachorn A; Braciale TJ
    J Virol; 1997 Jan; 71(1):678-85. PubMed ID: 8985399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions.
    Taylor G; Thomas LH; Furze JM; Cook RS; Wyld SG; Lerch R; Hardy R; Wertz GW
    J Gen Virol; 1997 Dec; 78 ( Pt 12)():3195-206. PubMed ID: 9400970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.
    Srikiatkhachorn A; Braciale TJ
    J Exp Med; 1997 Aug; 186(3):421-32. PubMed ID: 9236194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.
    Spender LC; Hussell T; Openshaw PJ
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1751-8. PubMed ID: 9680139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.
    Olson MR; Hartwig SM; Varga SM
    J Immunol; 2008 Dec; 181(11):7958-68. PubMed ID: 19017987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
    Hancock GE; Smith JD; Heers KM
    Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.
    Harker JA; Lee DC; Yamaguchi Y; Wang B; Bukreyev A; Collins PL; Tregoning JS; Openshaw PJ
    J Virol; 2010 May; 84(10):5294-302. PubMed ID: 20200251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice.
    Martinez X; Li X; Kovarik J; Klein M; Lambert PH; Siegrist CA
    Eur J Immunol; 1999 Oct; 29(10):3390-400. PubMed ID: 10540351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation.
    Bembridge GP; Rodriguez N; Garcia-Beato R; Nicolson C; Melero JA; Taylor G
    J Gen Virol; 2000 Oct; 81(Pt 10):2519-2523. PubMed ID: 10993942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
    Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.
    Hancock GE; Hahn DJ; Speelman DJ; Hildreth SW; Pillai S; McQueen K
    Vaccine; 1994; 12(3):267-74. PubMed ID: 8165859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.